New Injection Reduces Belly Fat Without Major Weight Loss. Scientists Are Testing What Happens Next

Key Points:

• Taiwan-based Caliway Biopharmaceuticals developed CBL-514, an experimental injection that induces fat cell death, showing an average 12.01% reduction in visceral abdominal fat four weeks post-treatment in early human trials.
• Phase 2 trial data presented at the 2026 European Association for the Study of Diabetes meeting revealed significant reductions in visceral fat compared to placebo, although overall body weight changes were minimal and the treatment remains unapproved in the U.S.
• Animal studies suggest CBL-514 may help reduce weight regain after stopping obesity medications like tirzepatide, pointing to potential use in maintaining weight loss, but this benefit has not yet been demonstrated in humans.
• Independent experts highlight the need for further research on CBL-514’s long-term safety, metabolic effects, and impact on health outcomes beyond fat reduction, noting mostly mild injection site reactions in trials so far.
• CBL-514 is currently in a Phase 3 clinical trial enrolling about 320 adults to assess effectiveness and safety, with no confirmed timeline for commercial availability, reflecting growing interest in novel obesity treatments that target fat storage mechanisms.